Abstract | BACKGROUND: AIM: METHODS: RESULTS: 162 patients were included; 104 had HBV markers (25 HBsAg positive) and 74 had HCV markers (51 HCV- RNA positive), and 16 patients had markers of both infections. Liver dysfunction was observed in 9 of 25 HBsAg positive patients (36%), 6 of whom developed hepatic failure. Liver dysfunction in HCV was observed in 8 of 51 HCV- RNA positive patients (15.7%), and only one developed hepatic failure. The frequency and severity of liver dysfunction was significantly higher in HBV-infected patients than in HCV-infected patients (p=0.045 and p=0.049, respectively). Treatment with ≥2 immunosuppressants was an independent predictor of HBV reactivation (OR 8.75; 95% CI 1.16 to 65.66). The majority of patients without reactivation received only one immunosuppressant for a short period and/or prophylactic antiviral treatment. No definite HBV reactivations were found in anti-HBc positive patients lacking HBsAg. CONCLUSION:
Liver dysfunction in patients with IBD treated with immunosuppressants is more frequent and severe in those with HBV than in HCV carriers and is associated with combined immunosuppression.
|
Authors | C Loras, J P Gisbert, M Mínguez, O Merino, L Bujanda, C Saro, E Domenech, J Barrio, M Andreu, I Ordás, L Vida, G Bastida, F González-Huix, M Piqueras, D Ginard, X Calvet, A Gutiérrez, A Abad, M Torres, J Panés, M Chaparro, I Pascual, M Rodriguez-Carballeira, F Fernández-Bañares, J M Viver, M Esteve, REPENTINA study, GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa) Group |
Journal | Gut
(Gut)
Vol. 59
Issue 10
Pg. 1340-6
(Oct 2010)
ISSN: 1468-3288 [Electronic] England |
PMID | 20577000
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adult
- Chemical and Drug Induced Liver Injury
(epidemiology, etiology)
- Female
- Hepacivirus
(physiology)
- Hepatitis B virus
(physiology)
- Hepatitis B, Chronic
(complications, epidemiology, immunology)
- Hepatitis C, Chronic
(complications, epidemiology, immunology)
- Humans
- Immunocompromised Host
- Immunosuppressive Agents
(adverse effects, therapeutic use)
- Inflammatory Bowel Diseases
(complications, drug therapy, epidemiology, immunology)
- Liver Cirrhosis
(epidemiology, immunology, virology)
- Male
- Middle Aged
- Opportunistic Infections
(complications, epidemiology, immunology)
- Spain
(epidemiology)
- Virus Activation
(drug effects)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|